Controllability Methods for Identifying Associations Between Critical Control ncRNAs and Human Diseases

  • Jose C. NacherEmail author
  • Tatsuya AkutsuEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1912)


Human diseases are not only associated to mutations in protein-coding genes. Contrary to what was thought decades ago, the human genome is largely transcribed which generates a large amount of nonprotein-coding RNAs (ncRNAs). Interestingly, these ncRNAs are not only able to perform biological functions and interact with other molecules such as proteins, but also have been reported involved in human diseases. In this book chapter, we review the recent research done on controllability methods related to associations between ncRNAs and human diseases. First, we introduce the bipartite complex network resulting from the interactions of ncRNAs and proteins. We then explain the theoretical background of controllability algorithms and apply these methods to the problem of identifying ncRNAs with critical roles in network control. Then, by performing statistical analyses we can answer the question on whether the subset of critical control ncRNAs is also enriched by human diseases. In addition, we review three-layer network models for prediction of ncRNA-disease associations.

Key words

Network controllability Noncoding RNA ncRNA-protein interactions Disease associations Bipartite networks Minimum dominating sets 



J.C.N. was partially supported by JSPS KAKENHI Grant Number JP25330351, and T.A. was partially supported by JSPS KAKENHI Grant Number 26540125. This research was partially supported by the Collaborative Research Program of Institute for Chemical Research, Kyoto University.


  1. 1.
    Collins LJ (2011) The RNA infrastructure: an introduction to ncRNA networks. Landes Bioscience and Springer Science+Business MediaGoogle Scholar
  2. 2.
    Collins LJ, Penny D (2009) RNA-infrastructure: dark matter of the eukaryotic cell? Trends Genet 25(3):120–128CrossRefGoogle Scholar
  3. 3.
    Mattick JS, Makunin IV (2006) Non-coding RNA. Hum Mol Genet 1:R17–R29CrossRefGoogle Scholar
  4. 4.
    Gesteland RF, Cech TR, Atkins JF (2006) The RNA World, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NYGoogle Scholar
  5. 5.
    Pang KC, Stephen S, Engström PG, Tajul-Arifin K, Chen W, Wahlestedt C, Lenhard B, Hayashizaki Y, Mattick JS (2005) RNAdb—a comprehensive mammalian non-coding RNA database. Nucleic Acids Res 33(database issue):D125–D130CrossRefGoogle Scholar
  6. 6.
    Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6:259–269CrossRefGoogle Scholar
  7. 7.
    Makeyev EV, Maniatis T (2008) Multilevel regulation of gene expression by MicroRNAs. Science 319:1789–1790CrossRefGoogle Scholar
  8. 8.
    Royo H, Cavaille J (2008) Non-coding RNAs in imprinted gene clusters. Biol Cell 100(3):149–166CrossRefGoogle Scholar
  9. 9.
    Costanzo M, Baryshnikova A, Bellay J et al (2010) The genetic landscape of a cell. Science 327(5964):425–431CrossRefGoogle Scholar
  10. 10.
    Collins LJ, Chen XS, Schonfeld B (2010) The epigenetics of non-coding RNA. In: Tollefsbol T (ed) Handbook of epigenetics. Academic Press, Oxford, pp 49–61Google Scholar
  11. 11.
    Gangaraju VK, Lin H (2009) MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 10(2):116–125CrossRefGoogle Scholar
  12. 12.
    He L et al (2005) A microRNA plycistron as a potential human oncogene. Nature 435:828–833CrossRefGoogle Scholar
  13. 13.
    Volinia S et al (2006) A microRNA expression signature of human solid tumors define gene targets. Proc Natl Acad Sci U S A 103:2257–2261CrossRefGoogle Scholar
  14. 14.
    Medina PP, Slack FJ (2008) MicroRNAs and cancer: an overview. Cell Cycle 7:2485–2492CrossRefGoogle Scholar
  15. 15.
    Drakaki A, Iliopoulos D (2009) MicroRNA gene networks in oncogenesis. Curr Genomics 10:35–41CrossRefGoogle Scholar
  16. 16.
    Roberts APE, Lewis AP, Jopling CL (2011) The role of microRNAs in viral infection. Prog Mol Biol Transl Sci 102:101–139CrossRefGoogle Scholar
  17. 17.
    Lin S, Gregory RI (2015) MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 15:321–333CrossRefGoogle Scholar
  18. 18.
    Alvarez-Garcia I, Miska EA (2005) MicroRNA functions in animal development and human disease. Development 132:4653–4662CrossRefGoogle Scholar
  19. 19.
    van Rooij E, Olson EN (2007) MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117:2369–2376CrossRefGoogle Scholar
  20. 20.
    Poy MN, Spranger M, Stoffel M (2007) MicroRNAs and the regulation of glucose and lipid metabolism. Diabetes Obes Metab 9:67–73CrossRefGoogle Scholar
  21. 21.
    Lu M et al (2008) An analysis of human microRNA and disease associations. PLoS One 3(10):e3420CrossRefGoogle Scholar
  22. 22.
    Van Rooij E, Olson EN (2012) MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 11:860–872CrossRefGoogle Scholar
  23. 23.
    Li Z, Rana TM (2014) Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 13:622–638CrossRefGoogle Scholar
  24. 24.
    Yuan J et al (2014) NPInter v2.0: an updated database of ncRNA interactions. Nucleic Acids Res 42:D104–D108CrossRefGoogle Scholar
  25. 25.
    Liu YY, Slotine JJ, Barabási AL (2011) Controllability of complex networks. Nature 473:167–173CrossRefGoogle Scholar
  26. 26.
    Nacher JC, Akutsu T (2012) Dominating scale-free networks with variable scaling exponent: heterogeneous networks are not difficult to control. New J Phys 14:073005CrossRefGoogle Scholar
  27. 27.
    Nacher JC, Akutsu T (2014) Analysis of critical and redundant nodes in controlling directed and undirected complex networks using dominating sets. J Complex Networks 2:394–412CrossRefGoogle Scholar
  28. 28.
    Nacher JC, Akutsu T (2013) Structural controllability of unidirectional bipartite networks. Sci Rep 3:1647CrossRefGoogle Scholar
  29. 29.
    Molnár F, Sreenivasan S, Szymanski BK, Korniss G (2013) Minimum dominating sets in scale-free network ensembles. Sci Rep 3:1736CrossRefGoogle Scholar
  30. 30.
    Wuchty S (2014) Controllability in protein interaction networks. Proc Natl Acad Sci U S A 111:7156–7160CrossRefGoogle Scholar
  31. 31.
    Sun PG (2015) Co-controllability of drug-disease-gene network. New J Phys 17:085009CrossRefGoogle Scholar
  32. 32.
    Khuri S, Wuchty S (2015) Essentiality and centrality in protein interaction networks. BMC Bioinformatics 16:109CrossRefGoogle Scholar
  33. 33.
    Zhang X-F, Ou-Yang L, Zhu Y, Wu M-Y, Dai D-Q (2015) Determining minimum set of driver nodes in protein-protein interaction networks. BMC Bioinformatics 16:146CrossRefGoogle Scholar
  34. 34.
    Ishitsuka M, Akutsu T, Nacher JC (2016) Critical controllability in proteome-wide protein interaction network integrating transcriptome. Sci Rep 6:23541CrossRefGoogle Scholar
  35. 35.
    Zhang X-F et al (2016) Comparative analysis of housekeeping and tissue-specific driver nodes in human protein interaction networks. BMC Bioinformatics 17:358CrossRefGoogle Scholar
  36. 36.
    Nacher JC, Akutsu T (2016) Minimum dominating set-based methods for analyzing biological networks. Methods 102:57–63CrossRefGoogle Scholar
  37. 37.
    Jia T et al (2013) Emergence of bimodality in controlling complex networks. Nat Commun 4:2002CrossRefGoogle Scholar
  38. 38.
    Li Y et al (2014) HMDD v2.0: a database for experimentally supported human microRNA and disease associations. Nucleic Acids Res 42:D1070–D1074CrossRefGoogle Scholar
  39. 39.
    Rossi S et al (2011) OMiR: identification of associations between OMIM diseases and microRNAs. Genomics 97:71–76CrossRefGoogle Scholar
  40. 40.
    Kagami H, Akutsu T, Nacher JC (2015) Determining associations between human diseases and non-coding RNAs with critical roles in network control. Sci Rep 5:14577CrossRefGoogle Scholar
  41. 41.
    Alaimo S, Giugno R, Pulvirenti A (2014) ncPred: ncRNA-disease association prediction through tripartite network-based inference. Front Bioeng Biotechnol 2:71CrossRefGoogle Scholar
  42. 42.
    Mori T, Ngouv H, Hayashida M, Akutsu T, Nacher JC (2018) ncRNA-disease association prediction based on sequence information and tripartite network. BMC Syst Biol 12(Suppl 1):37CrossRefGoogle Scholar
  43. 43.
    Zhu JJ, Fu HJ, Wu YG, Zheng XF (2013) Function of lncRNAs and approaches to lncRNA-protein interactions. Sci China Life Sci 56:876–885CrossRefGoogle Scholar
  44. 44.
    Fatica A, Bozzoni I (2014) Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 15:7–21CrossRefGoogle Scholar
  45. 45.
    Madamanchi NR et al (2002) A noncoding RNA regulates human protease activated receptor-1 gene during embryogenesis. Biochim Biophys Acta 1576(3):237–245CrossRefGoogle Scholar
  46. 46.
    Colombo T, Farina L, Macino G, Paci P (2015) PVT1: a rising star among oncogenic long noncoding RNAs. BioMed Res Int 2015:304208 10 ppCrossRefGoogle Scholar
  47. 47.
    Mogilyansky E, Rigoutsos I (2013) The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 20:1603–1614CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Faculty of Science, Department of Information ScienceToho UniversityChibaJapan
  2. 2.Bioinformatics Center, Institute for Chemical ResearchKyoto UniversityKyotoJapan

Personalised recommendations